

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 February 2019 (21.02.2019)



(10) International Publication Number
WO 2019/036460 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) *C07K 16/40* (2006.01)
A61K 38/48 (2006.01) *C12N 9/50* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2018/046690

(22) International Filing Date:

14 August 2018 (14.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/545,864	15 August 2017 (15.08.2017)	US
62/574,690	19 October 2017 (19.10.2017)	US
62/630,756	14 February 2018 (14.02.2018)	US
62/637,281	01 March 2018 (01.03.2018)	US

(71) Applicants: **OMEROS CORPORATION** [US/US]; 201 Elliott Avenue West, Seattle, WA 98119 (US). **UNIVERSI-**

TY OF LEICESTER [GB/GB]; University Road, Leicester LE1 7RH (GB).


(72) Inventors: **DEMOPULOS, Gregory A.**; 4845 Forest Avenue SE, Mercer Island, WA 98040 (US). **DUDLER, Thomas**; 13410 NE 36th Street, Bellevue, WA 98005 (US). **SCHWAEBLE, Hans-Wilhelm**; 36 The Green, Mountsorrel, Leicestershire LE12 7AF (GB).

(74) Agent: **QUINTON, Tineka J.**; Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: METHODS FOR TREATING AND/OR PREVENTING GRAFT-VERSUS-HOST DISEASE AND/OR DIFFUSE ALVEOLAR HEMORRHAGE AND/OR VENO-OCCLUSIVE DISEASE ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANT

FIGURE 61



(57) Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft- versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*